Squarepoint Ops LLC Has $2.08 Million Stake in InMode Ltd. $INMD

Squarepoint Ops LLC increased its stake in InMode Ltd. (NASDAQ:INMD) by 92.9% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 143,758 shares of the healthcare company’s stock after purchasing an additional 69,239 shares during the quarter. Squarepoint Ops LLC owned approximately 0.23% of InMode worth $2,076,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Parallel Advisors LLC lifted its stake in shares of InMode by 63.1% in the second quarter. Parallel Advisors LLC now owns 1,973 shares of the healthcare company’s stock worth $28,000 after buying an additional 763 shares during the last quarter. Farther Finance Advisors LLC lifted its position in InMode by 302.3% during the 2nd quarter. Farther Finance Advisors LLC now owns 8,110 shares of the healthcare company’s stock worth $117,000 after acquiring an additional 6,094 shares during the last quarter. Ritholtz Wealth Management bought a new stake in InMode during the second quarter valued at about $151,000. Topline Capital Management LLC bought a new stake in InMode during the second quarter valued at about $160,000. Finally, Caption Management LLC bought a new position in shares of InMode in the first quarter worth about $219,000. Institutional investors own 68.04% of the company’s stock.

InMode Price Performance

Shares of INMD stock opened at $14.56 on Friday. InMode Ltd. has a one year low of $13.14 and a one year high of $19.78. The stock has a fifty day moving average price of $14.64 and a 200 day moving average price of $14.58. The stock has a market cap of $920.34 million, a P/E ratio of 6.74 and a beta of 2.14.

Wall Street Analyst Weigh In

INMD has been the subject of several recent analyst reports. UBS Group decreased their target price on InMode from $16.25 to $16.00 and set a “neutral” rating for the company in a research note on Thursday, November 6th. Weiss Ratings reissued a “sell (d+)” rating on shares of InMode in a research report on Wednesday, October 8th. Wall Street Zen lowered shares of InMode from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Zacks Research raised shares of InMode from a “strong sell” rating to a “hold” rating in a report on Monday, September 29th. Finally, Canaccord Genuity Group set a $15.00 price target on shares of InMode and gave the stock a “hold” rating in a research report on Wednesday. One analyst has rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $16.60.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.